This article is more than 5 years old. Information may no longer be current.

Alcon reports $1.47 billion in global fourth quarter sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Alcon recorded $1.47 billion in global sales for the fourth quarter of 2007, an increase of 20% over global sales for the fourth quarter of 2006, the company announced in a press release.

Alcon's fourth quarter earnings included $15.1 million in product sales under the aegis of WaveLight AG because the company acquired 77.4% of WaveLight's outstanding shares in November.

Net earnings for the fourth quarter were $376.5 million, or $1.25 per diluted share, compared with $354.7 million, or $1.16 per diluted share, for the fourth quarter of 2006.

Adjusted net earnings for the fourth quarter - excluding a $16.8 million after-tax deficit related to the acquisition and assimilation of WaveLight - were $393.3 million, or $1.31 per diluted share, for an increase of 10.9% compared with the fourth quarter of 2006, according to the release.

For the full year 2007, Alcon reported global sales of $5.6 billion, a 14.4% increase from $4.9 billion in 2006. Net earnings for the full year rose 17.7% to $1.59 billion, or $5.25 per diluted share, compared with $1.34 billion, or $4.37 per share, for the full year 2006, the release said.

Breaking down proceeds by product, Alcon reported fourth quarter pharmaceutical sales of $578.2 million, a 21.5% rise from the fourth quarter of 2006. Specifically, sales of glaucoma products increased 28.3% to $236.5 million, spearheaded by rising sales of Travatan (travoprost) and Azopt ophthalmic suspension (brinzolamide).

Travatan sales alone rose by 38.7%, the release said.

Surgical sales, including $15.1 million generated by WaveLight AG after the acquisition, rose 20.3% to $700.8 million.

Fourth quarter IOL sales were $259.3 million, an increase of 24.3% from the fourth quarter 2006. In particular, global sales of premium IOLs rose 45.6% to $40.4 million, according to the release.

Alcon's fourth quarter refractive earnings rose 75.4%, owing in part to revenue produced by WaveLight after the acquisition.

Additionally, consumer eye care sales increased 14.5% to $190.7 million, according to the release.